Together, these experiments clearly demonstrate that JMJD2B is induced upon p53 activation, in different cancer cell lines, either upon DNA damage or increased p53 stabilization by Nutlin-3, supporting the concept that JMJD2B is a bona fide p53 target. The gene discussed is KDM4B; the disease is cancer.